The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.
 
Michael Siavash Khodadoust
No Relationships to Disclose
 
Michael Patvin Chu
No Relationships to Disclose
 
Debra Czerwinski
No Relationships to Disclose
 
Kathleen McDonald
No Relationships to Disclose
 
Steven Long
No Relationships to Disclose
 
Holbrook Edwin Kohrt
No Relationships to Disclose
 
Richard T. Hoppe
Stock and Other Ownership Interests - Johnson & Johnson; Pfizer
Honoraria - Clarient; Takeda
Consulting or Advisory Role - Clarient
Travel, Accommodations, Expenses - Takeda
 
Ranjana H. Advani
Honoraria - Eisai; GE Healthcare; Millennium
Research Funding - Agensys (Inst); Allos Therapeutics (Inst); Celgene (Inst); Genentech/Roche (Inst); Idera (Inst); Janssen (Inst); Millennium (Inst); Pharmacyclics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genentech; Seagen
 
Robert Lowsky
No Relationships to Disclose
 
Ronald Levy
Stock and Other Ownership Interests - Merck
Consulting or Advisory Role - BeiGene; Bullet Bio; Five Prime Therapeutics; ImmunoCellular Therapeutics; Inate Pharma; Kite, a Gilead company
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Pharmacyclics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline